Benlysta® Belimumab 400 mg Injection - Treatment for Systemic Lupus Erythematosus (SLE) and Lupus Nephritis

USAMP#28944529SKU: 49401010201Benlysta®
rxLicense

License Required

wishlistAltwishlistAlt
Benlysta Belimumab 400 mg for SLE & Lupus Nephritis

Product Spotlight

  • Benlysta® (Belimumab) is a targeted B-lymphocyte stimulator (BLyS)-specific inhibitor, designed to treat autoantibody-positive systemic lupus erythematosus (SLE) in patients 5 years and older, alongside standard therapy.
  • It is also approved for the management of adult patients with active lupus nephritis, as part of a comprehensive treatment plan.
  • Benlysta® is a sterile, preservative-free injection, ensuring safety and efficacy for immune system modulation.
  • Designed for single-use in a 20 mL vial, this 400 mg formulation requires refrigeration to maintain its stability and potency.